Please login to the form below

Not currently logged in
Email:
Password:

PCSK9

This page shows the latest PCSK9 news and features for those working in and with pharma, biotech and healthcare.

Sanofi gets cardio outcomes claim for Praluent in EU

Sanofi gets cardio outcomes claim for Praluent in EU

The two PCSK9 inhibitors are locked in a battle for the severe, high-risk end of the cholesterol market – mainly patients who are unable to control low-density lipoprotein (LDL) cholesterol ... Complicating the picture is a global intellectual property

Latest news

More from news
Approximately 16 fully matching, plus 60 partially matching documents found.

Latest Intelligence

  • Astellas: Ten years young Astellas: Ten years young

    With the partners gearing up to launch Amgen's PCSK9 therapy for hypercholesterolemia - a class of drugs that is top of many peoples' minds - it's an approach that seems to

  • Pharma deals in September 2015 Pharma deals in September 2015

    Amgen's busy month (part 2). Following FDA approval for its novel PCSK9 treatment for “bad cholesterol”, Amgen is moving onto tackle dyslipidemia, an asymptomatic disease in which serum lipid levels

  • Going the distance Going the distance

    Looking to the second half of this year and Sanofi is aiming for a Q3 launch for its new PCSK9 cardiovascular disease management drug Praluent (alirocumab), which comes from its collaboration

  • Pharma deals during November 2014 Pharma deals during November 2014

    In July, BioMarin sold its PRV to Regeneron for $68m to expedite filing of its cholesterol drug, the PCSK9 inhibitor alirocumab, being developed in partnership with Sanofi.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics